U.S. Consumer Durables Stock News

NYSE:LNG
NYSE:LNGOil and Gas

Cheniere Energy Upgrades Highlight LNG Tailwinds And Valuation Gap

Multiple major brokerages have recently upgraded their outlook on Cheniere Energy (NYSE:LNG). Analysts point to improving liquefied natural gas, or LNG, market fundamentals as a key driver. Positive industry developments and progress on U.S. LNG projects are central to the upgraded views. Cheniere Energy is a leading U.S. exporter of liquefied natural gas, connecting domestic natural gas production to global buyers. The recent wave of upgrades comes as LNG demand signals and project...
NYSE:USB
NYSE:USBBanks

USB Q3 Net Interest Margin Resilience Tests Bullish Efficiency Narratives

U.S. Bancorp (USB) just posted another solid update, with third quarter FY 2025 revenue at US$6.7b and EPS at US$1.22, giving investors a clear look at the bank's current earnings power. Over recent quarters, revenue has moved from US$6.3b in Q3 FY 2024 to US$6.4b in Q4 FY 2024 and then to US$6.7b in Q3 FY 2025, while quarterly EPS has ranged from about US$1.01 to US$1.22 across that same stretch. With net income holding in the US$1.6b to US$1.9b range and profitability supported by metrics...
NYSE:KEY
NYSE:KEYBanks

KeyCorp (KEY) Net Interest Margin Rebound Tests Bearish Narratives On Profitability

KeyCorp (KEY) just posted another solid quarter, with Q3 FY 2025 revenue at US$1,779 million and basic EPS of US$0.41, while trailing twelve month revenue sat at US$5,934 million and EPS at US$0.87. Over the past few reporting periods, revenue has moved from US$816 million in Q4 2024 to US$1,646 million in Q1 2025, US$1,693 million in Q2 2025 and now US$1,779 million in Q3 2025. Quarterly EPS has shifted from a loss of US$0.28 in Q4 2024 to US$0.34, US$0.35 and US$0.41 respectively. With that...
NasdaqGS:ASND
NasdaqGS:ASNDBiotechs

Ascendis Pharma Achondroplasia Data Highlights Emerging Rare Disease Franchise Potential

Ascendis Pharma (NasdaqGS:ASND) reported positive topline Week 52 results from its COACH Phase 2 trial in children with achondroplasia. The combination therapy showed durable growth, improved body proportionality, and a favorable safety profile over the 52 week period. The data support the company’s achondroplasia program as a potential backbone treatment approach for pediatric patients. Ascendis Pharma, a biopharmaceutical company focused on endocrinology related rare diseases, is...
NasdaqGS:PEBO
NasdaqGS:PEBOBanks

Peoples Bancorp (PEBO) Net Interest Margin Stability Tests Bullish Narratives In Q3 Results

Peoples Bancorp (PEBO) has put up a solid set of headline numbers for FY 2025 Q3, with total revenue of US$107.9 million, basic EPS of US$0.83 and net income of US$29.2 million, while its net profit margin over the last twelve months sits at 18.2% compared with 24.6% a year earlier. Over recent quarters the company has seen revenue move from US$106.97 million in FY 2024 Q3 to US$97.82 million in FY 2025 Q2 and then to US$107.9 million in FY 2025 Q3, alongside quarterly EPS prints of US$0.90,...
NasdaqGS:MBWM
NasdaqGS:MBWMBanks

Mercantile Bank (MBWM) Earnings Steady As 3.5% Net Interest Margin Challenges Margin Squeeze Narrative

Mercantile Bank (MBWM) just posted its FY 2025 third quarter numbers with total revenue of US$62.2 million and basic EPS of US$1.46, alongside net income, excluding extra items, of US$23.8 million, giving investors a clean read on core profitability. The bank has seen revenue move from US$56.9 million in Q3 2024 to US$62.2 million in Q3 2025, while quarterly EPS has shifted from about US$1.22 to US$1.46 over the same period. Trailing twelve month EPS is roughly US$5.28, and investors are...
NasdaqGM:CSTL
NasdaqGM:CSTLHealthcare

How Investors Are Reacting To Castle Biosciences (CSTL) Upgraded 2025 Revenue Outlook And Test Volume Growth

In January 2026, Castle Biosciences reported that 2025 total revenue is expected to exceed US$340 million, above its prior US$327–US$335 million range, alongside strong year-on-year growth in test volumes for its core DecisionDx-Melanoma and TissueCypher Barrett’s Esophagus assays. The sharp increase in core test reports, particularly for TissueCypher, suggests that Castle’s efforts to broaden clinical adoption and utilization are gaining traction across its key diagnostic franchises. Now...
NasdaqGS:VLY
NasdaqGS:VLYBanks

3 Stocks Estimated To Be Trading At Discounts Of Up To 48.8%

Recent developments in the U.S. stock market have been marked by volatility, with major indices such as the Dow Jones and S&P 500 experiencing declines amid geopolitical tensions and rising bond yields. In this environment, investors often seek opportunities in undervalued stocks that may be trading at significant discounts, offering potential for growth when market conditions stabilize.
NYSE:GPRK
NYSE:GPRKOil and Gas

Top Insider-Owned Growth Companies In January 2026

As the U.S. stock market faces turbulence with major indices like the Dow Jones and S&P 500 experiencing declines due to geopolitical tensions, investors are increasingly turning their attention to growth companies with strong insider ownership. In such uncertain times, these firms can offer a unique appeal, as high insider ownership often signals confidence from those who know the company best and may provide stability amid broader market volatility.
NYSE:MX
NYSE:MXSemiconductor

3 Promising Penny Stocks With Market Caps Under $300M

The U.S. stock market has recently been rattled by geopolitical tensions, with major indices experiencing declines amid tariff threats and surging bond yields. In such a volatile landscape, investors often turn their attention to smaller companies that might offer unique opportunities. Penny stocks, despite the outdated term, remain relevant as they represent smaller or newer firms that can provide significant value when backed by strong financials. This article highlights three penny stocks...
NYSE:TCI
NYSE:TCIReal Estate

US Undiscovered Gems To Watch In January 2026

As the U.S. market grapples with geopolitical tensions and fluctuating bond yields, small-cap stocks in the S&P 600 have shown resilience amid broader market volatility. With major indices like the Dow Jones and Nasdaq experiencing declines due to tariff threats, investors are increasingly turning their attention to lesser-known opportunities that may offer growth potential in uncertain times. In this context, identifying a good stock often involves looking for companies with strong...
NYSE:FBK
NYSE:FBKBanks

Arthur J. Gallagher And 2 Other Companies That May Be Priced Below Their Estimated Value

As U.S. markets experience weekly losses amid rising Treasury yields and economic uncertainty, investors are increasingly on the lookout for stocks that may be undervalued relative to their intrinsic worth. In this environment, identifying companies like Arthur J. Gallagher and others that could be priced below their estimated value can offer potential opportunities for those looking to navigate the current financial landscape effectively.
NasdaqCM:CV
NasdaqCM:CVMedical Equipment

Insider-Owned Growth Stocks Poised For Success In January 2026

As U.S. markets navigate a landscape of rising Treasury yields and uncertainty surrounding Federal Reserve policies, investors are keenly observing insider activities as a potential indicator of confidence in company growth prospects. In this climate, stocks with high insider ownership may signal strong alignment between management and shareholders, which can be particularly appealing when market conditions are volatile.
NasdaqCM:AACG
NasdaqCM:AACGConsumer Services

ATA Creativity Global Among 3 Promising Penny Stocks

As the U.S. stock market faces a challenging period with major indexes posting weekly losses and Treasury yields reaching a four-month high, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking growth prospects outside of the mainstream market giants. Despite being considered somewhat niche today, penny stocks can still offer significant potential when backed by...
NasdaqGS:GSBC
NasdaqGS:GSBCBanks

Undiscovered Gems in the US Market for January 2026

As the U.S. market faces headwinds with major indexes posting weekly losses and Treasury yields reaching a four-month high, investors are keenly observing how these dynamics impact small-cap stocks, which often feel the effects of economic shifts more acutely. In such a climate, identifying undiscovered gems requires focusing on companies with strong fundamentals and growth potential that can weather broader market uncertainties.
NYSE:TRNO
NYSE:TRNOIndustrial REITs

Top Dividend Stocks To Consider In January 2026

As the U.S. markets navigate recent fluctuations with major indexes posting weekly losses amid rising Treasury yields, investors are keenly observing the Federal Reserve's next moves and their potential impact on interest rates. In this environment of uncertainty, dividend stocks can offer a sense of stability and income generation, making them an attractive consideration for those looking to balance growth with consistent returns.